https://www.selleckchem.com/TGF-beta.html
e associated with a low bleeding risk. Our data support consideration of a 2-4 week trial of antithrombotic therapy, usually starting with antiplatelet therapy, in aPL-positive patients with refractory migraine, particularly if other treatment options have been exhausted. As a retrospective study, our data provide only Class IV level of evidence, but they suggest randomized controlled trials are warranted to validate these encouraging findings. Despite increased physician's awareness and improved diagnostic and serological testing in the recent
Curtir
Comentario
Compartilhar
